Last reviewed · How we verify
delta-24-RGD adenovirus
At a glance
| Generic name | delta-24-RGD adenovirus |
|---|---|
| Sponsor | Erasmus Medical Center |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (PHASE2)
- DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas (PHASE1)
- DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (PHASE1)
- Virus DNX2401 and Temozolomide in Recurrent Glioblastoma (PHASE1)
- Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma (PHASE1, PHASE2)
- Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- delta-24-RGD adenovirus CI brief — competitive landscape report
- delta-24-RGD adenovirus updates RSS · CI watch RSS
- Erasmus Medical Center portfolio CI